MA52375B2 - Inhibiteurs de cdk8/19 - Google Patents
Inhibiteurs de cdk8/19Info
- Publication number
- MA52375B2 MA52375B2 MA52375A MA52375A MA52375B2 MA 52375 B2 MA52375 B2 MA 52375B2 MA 52375 A MA52375 A MA 52375A MA 52375 A MA52375 A MA 52375A MA 52375 B2 MA52375 B2 MA 52375B2
- Authority
- MA
- Morocco
- Prior art keywords
- cdk8
- inhibitors
- compounds
- disorders
- possess
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2018128415A RU2761824C2 (ru) | 2018-08-03 | 2018-08-03 | Ингибиторы CDK8/19 |
| PCT/RU2019/050123 WO2020027704A1 (ru) | 2018-08-03 | 2019-07-31 | Ингибиторы cdk8/19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA52375A1 MA52375A1 (fr) | 2021-12-31 |
| MA52375B2 true MA52375B2 (fr) | 2023-02-28 |
Family
ID=69231230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA52375A MA52375B2 (fr) | 2018-08-03 | 2019-07-31 | Inhibiteurs de cdk8/19 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11840531B2 (https=) |
| EP (1) | EP3831829A4 (https=) |
| JP (1) | JP7365396B2 (https=) |
| KR (1) | KR102926889B1 (https=) |
| CN (1) | CN113166140B (https=) |
| AR (1) | AR115898A1 (https=) |
| AU (1) | AU2019313199B2 (https=) |
| BR (1) | BR112021001939A2 (https=) |
| CA (1) | CA3108298A1 (https=) |
| CL (1) | CL2021000282A1 (https=) |
| CO (1) | CO2021001174A2 (https=) |
| EA (1) | EA202190452A1 (https=) |
| MA (1) | MA52375B2 (https=) |
| MX (1) | MX2021001335A (https=) |
| PE (1) | PE20210416A1 (https=) |
| PH (1) | PH12021550258A1 (https=) |
| RU (1) | RU2761824C2 (https=) |
| TW (1) | TWI839374B (https=) |
| WO (1) | WO2020027704A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023533016A (ja) | 2020-07-11 | 2023-08-01 | ファイザー・インク | 抗ウイルス性ヘテロアリールケトン誘導体 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| WO2024109660A1 (zh) * | 2022-11-21 | 2024-05-30 | 上海齐鲁制药研究中心有限公司 | Cdk抑制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR060358A1 (es) * | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
| MX2010006244A (es) * | 2007-12-06 | 2010-12-02 | Schering Corp | Moduladores de gamma secretasa. |
| CN103249721B (zh) * | 2010-10-18 | 2016-10-12 | 拉夸里亚创药株式会社 | 作为ttx-s阻滞剂的芳胺衍生物 |
| TWI529171B (zh) * | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | １，７－萘啶衍生物 |
| JP2017522324A (ja) | 2014-07-17 | 2017-08-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用 |
| EP3383875B1 (en) * | 2015-11-30 | 2022-02-09 | Council Of Scientific & Industrial Research | 3-pyrimidinyl pyrrolo [2,3-b] pyridine as anticancer agents and the process for the preparation thereof |
| US11213520B2 (en) * | 2016-05-23 | 2022-01-04 | Boehringer Ingelheim International Gmbh | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors |
-
2018
- 2018-08-03 RU RU2018128415A patent/RU2761824C2/ru active
-
2019
- 2019-07-31 MA MA52375A patent/MA52375B2/fr unknown
- 2019-07-31 PE PE2021000162A patent/PE20210416A1/es unknown
- 2019-07-31 US US17/264,670 patent/US11840531B2/en active Active
- 2019-07-31 MX MX2021001335A patent/MX2021001335A/es unknown
- 2019-07-31 AU AU2019313199A patent/AU2019313199B2/en active Active
- 2019-07-31 WO PCT/RU2019/050123 patent/WO2020027704A1/ru not_active Ceased
- 2019-07-31 KR KR1020217006527A patent/KR102926889B1/ko active Active
- 2019-07-31 EP EP19844331.9A patent/EP3831829A4/en active Pending
- 2019-07-31 JP JP2021505964A patent/JP7365396B2/ja active Active
- 2019-07-31 CA CA3108298A patent/CA3108298A1/en active Pending
- 2019-07-31 CN CN201980065665.1A patent/CN113166140B/zh active Active
- 2019-07-31 BR BR112021001939-1A patent/BR112021001939A2/pt unknown
- 2019-07-31 EA EA202190452A patent/EA202190452A1/ru unknown
- 2019-08-02 TW TW108127569A patent/TWI839374B/zh active
- 2019-08-02 AR ARP190102200A patent/AR115898A1/es unknown
-
2021
- 2021-02-02 CL CL2021000282A patent/CL2021000282A1/es unknown
- 2021-02-02 CO CONC2021/0001174A patent/CO2021001174A2/es unknown
- 2021-02-03 PH PH12021550258A patent/PH12021550258A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202012406A (zh) | 2020-04-01 |
| AU2019313199A1 (en) | 2021-03-11 |
| RU2018128415A (ru) | 2020-02-04 |
| PE20210416A1 (es) | 2021-03-04 |
| CO2021001174A2 (es) | 2021-02-26 |
| BR112021001939A2 (pt) | 2021-04-27 |
| MX2021001335A (es) | 2021-04-12 |
| CN113166140B (zh) | 2024-06-14 |
| CN113166140A (zh) | 2021-07-23 |
| EP3831829A1 (en) | 2021-06-09 |
| CL2021000282A1 (es) | 2021-08-13 |
| RU2761824C2 (ru) | 2021-12-13 |
| JP7365396B2 (ja) | 2023-10-19 |
| AR115898A1 (es) | 2021-03-10 |
| AU2019313199B2 (en) | 2023-07-06 |
| RU2018128415A3 (https=) | 2021-03-30 |
| EA202190452A1 (ru) | 2021-04-13 |
| US11840531B2 (en) | 2023-12-12 |
| PH12021550258A1 (en) | 2021-10-11 |
| WO2020027704A1 (ru) | 2020-02-06 |
| TWI839374B (zh) | 2024-04-21 |
| MA52375A1 (fr) | 2021-12-31 |
| US20210246138A1 (en) | 2021-08-12 |
| KR102926889B1 (ko) | 2026-02-19 |
| EP3831829A4 (en) | 2022-04-20 |
| CA3108298A1 (en) | 2020-02-06 |
| KR20210040416A (ko) | 2021-04-13 |
| JP2021533143A (ja) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA57972B1 (fr) | Inhibiteurs de parp1 | |
| MA51530B1 (fr) | Composés cycliques fondus | |
| MA57908B1 (fr) | Composés macrocycliques substitués et méthodes de traitement associées | |
| MA64509B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA64121B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA47368B1 (fr) | N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga | |
| MA37762A1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| MA54133B1 (fr) | Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y | |
| TN2010000230A1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA35459B1 (fr) | Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit | |
| MA37439A1 (fr) | Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1). | |
| MA43409B1 (fr) | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
| MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
| MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
| EP2091328A4 (en) | SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
| MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA34599B1 (fr) | Compositions pharmaceutiques contenant un inhibiteur dgat1 | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
| MA38810B1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
| MA52375B2 (fr) | Inhibiteurs de cdk8/19 | |
| MA68743B1 (fr) | Composés et compositions pour le traitement d'états associés à l'activité du récepteur de lpa |